Kisho

Oncovir — Rare Disease Pipeline | Kisho

Oncovir

Other

Orphan Designations

0 approved, 4 designated

FDA Approvals

Active Trials

Rare Diseases

across 17 areas

News (30d)

Quiet

Oncovir is a company with 4 orphan drug designations across 9 rare diseases. 1 active policy bill affects their portfolio.

Competitive Landscape

Diversified Portfolio

Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.

Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA

Approved: 0

In Trials: 0

Designated Only: 9

9 total diseases

Disease	Drug(s)	Stage
Angelman syndrome	polyinosinic-polycytidilic acid	Des.TrialAppr.
acute sensory ataxic neuropathy	polyinosinic-polycytidilic acid	Des.TrialAppr.
aortic valve stenosis	polyinosinic-polycytidilic acid	Des.TrialAppr.
brain cancer	Poly-ICLC	Des.TrialAppr.
brainstem cancer	Poly-ICLC	Des.TrialAppr.
malignant carotid body paraganglioma	polyinosinic-polycytidilic acid (Poly-ICLC)	Des.TrialAppr.
post-treatment Lyme disease syndrome	polyinosinic-polycytidilic acid (Poly-ICLC)	Des.TrialAppr.
primary brain neoplasm	Poly-ICLC	Des.TrialAppr.
treatment-refractory schizophrenia	polyinosinic-polycytidilic acid (Poly-ICLC)	Des.TrialAppr.